Literature DB >> 12381547

The medical management of Cushing's syndrome.

Damian Morris1, Ashley Grossman.   

Abstract

Cushing's syndrome results from prolonged exposure to excessive circulating glucocorticosteroids, and is associated with significant morbidity and mortality. While the treatment of choice in most patients is surgical, the metabolic consequences of the syndrome, including increased tissue fragility, poor wound healing, hypertension, and diabetes mellitus, increase the risks of such surgery. The hypercortisolemia and its sequelae can be efficiently reversed using medical therapy, either as a temporary measure prior to definitive treatment, or longer term in more difficult cases. Drug treatment has been targeted at the hypothalamic/pituitary level, the adrenal glands, and also at the glucocorticoid receptor level. In this review we discuss the pharmacotherapeutic agents that have been used in Cushing's syndrome, and their efficacy, the monitoring of treatment, and potential therapies that may prove useful in the future in this complex endocrinological disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381547     DOI: 10.1111/j.1749-6632.2002.tb04418.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

Review 1.  Novel medical approaches for the treatment of Cushing's disease.

Authors:  A P Heaney
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 2.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

Review 3.  PPAR-gamma in Cushing's disease.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 4.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 5.  The ectopic ACTH syndrome.

Authors:  Krystallenia I Alexandraki; Ashley B Grossman
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

6.  Ectopic ACTH syndrome caused by pheochromocytoma: computed tomography-guided percutaneous ethanol injection as an alternative treatment.

Authors:  D L Danilovic; R A Brandão Neto; H D'Abronzo; M R Menezes; A M Lucon; B B Mendonca
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

Review 7.  Hypertension and adrenal disorders.

Authors:  Wassim Chemaitilly; Robert C Wilson; Maria I New
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

Review 8.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 9.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.